NIH launches clinical trial of mRNA Nipah virus vaccine

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an investigational vaccine to prevent infection with Nipah virus. The experimental vaccine is manufactured by Moderna, Inc., (Cambridge, Massachusetts) and was developed in collaboration with NIAID's Vaccine Research Center. It is based on a messenger RNA (mRNA) platform - a technology used in several approved COVID-19 vaccines.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news